Immunocore doses first subject in gastrointestinal cancer therapy trial

Immunocore Holdings has dosed the first subject in a multicentre Phase I/II trial of IMC-R117C, a PIWIL1-targeted immunotherapy, for...
14 hours ago
from: Yahoo Finance

Colorectal cancer, Gastrointestinal cancer, ImmTAC, Immunocore, Immunotherapy, Oncology, PIWIL1

More about this

- Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care,...
from: The Manila Times

- Immunocore Launches Groundbreaking PIWIL1 Cancer Trial: First-Ever Immunotherapy Targeting Colorectal Cancer
Immunocore (IMCR) has initiated patient treatment in a Phase 1/2 trial for IMC-R117C, their fifth ImmTAC candidate, targeting PIWIL1 in...
from: Stock Titan

- Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care,...
from: The Manila Times